The results of this collaboration may help Abbott’s drug discovery programs develop drugs that are effective for a wider range of patients.
Abbott will fund the research under this collaboration and Myriad will use its high-throughput sequencing technologies and proprietary mutation screening software to analyze samples from various populations to identify genetic polymorphisms, or differences in the DNA between individuals.
“We are pleased to once again extend our successful relationship with Abbott in pharmacogenetics, an area in which Myriad can apply its proprietary technologies,” said Peter Meldrum, president and CEO of Myriad Genetics. “There is significant potential through this collaboration to develop new personalized medicine products in areas of important and growing healthcare needs.”